Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Viking Therapeutics, Inc. - Common Stock
(NQ:
VKTX
)
32.10
-0.28 (-0.86%)
Streaming Delayed Price
Updated: 11:43 AM EST, Jan 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Viking Therapeutics, Inc. - Common Stock
< Previous
1
2
...
23
24
25
26
27
28
29
30
Next >
Viking Therapeutics Earnings Preview
↗
April 26, 2022
Viking Therapeutics (NASDAQ:VKTX) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Viking...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
April 26, 2022
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
April 19, 2022
On Tuesday, 242 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was...
Via
Benzinga
Viking Therapeutics: Q4 Earnings Insights
↗
February 09, 2022
Viking Therapeutics (NASDAQ:VKTX) reported its Q4 earnings results on Wednesday, February 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 9, 2022
↗
February 09, 2022
Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
March 15, 2022
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
February 11, 2022
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.6% to $1.35 during Friday's regular session. As of 12:30 EST, Dermata Therapeutics's stock is...
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
↗
February 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
↗
February 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
January 18, 2022
Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a...
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
↗
July 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...
Via
Benzinga
Earnings Scheduled For July 28, 2021
↗
July 28, 2021
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.55 per share on revenue of $7.90 billion. • United...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
February 07, 2022
Gainers Agile Therapeutics (NASDAQ:AGRX) ...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
February 01, 2022
Gainers Epizyme (NASDAQ:EPZM) shares incr...
Via
Benzinga
Viking Therapeutics' Early Stage Trial On FDA Hold In Rare Metabolic Disorder
↗
January 24, 2022
The FDA has placed a clinical hold on Viking Therapeutics Inc's (NASDAQ: VKTX) Phase 1b trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
January 03, 2022
Gainers Indaptus Therapeutics (NASDAQ:INDP
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
↗
January 14, 2022
During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
↗
January 06, 2022
On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this...
Via
Benzinga
Viking Therapeutics (VKTX) Q3 2021 Earnings Call Transcript
↗
November 04, 2021
VKTX earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
↗
November 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...
Via
Benzinga
Topics
Retirement
12 Health Care Stocks Moving In Friday's After-Market Session
↗
September 10, 2021
Gainers Hepion Pharmaceuticals (NASDAQ:HEPA
Via
Benzinga
Earnings Scheduled For November 3, 2021
↗
November 03, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion....
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
↗
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
September 03, 2021
Gainers Enveric Biosciences (NASDAQ:ENVB...
Via
Benzinga
Viking Therapeutics (VKTX) Q2 2021 Earnings Call Transcript
↗
July 29, 2021
VKTX earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
↗
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...
Via
Benzinga
Why Viking Therapeutics Stock Briefly Popped Today
↗
June 17, 2021
An early-stage study gave investors reasons to cheer this morning.
Via
The Motley Fool
Viking Therapeutics' VK0214 Shows Encouraging Safety, Tolerability Profile In Healthy Volunteers
↗
June 17, 2021
Viking Therapeutics Inc (NASDAQ: VKTX) has announced results from its Phase 1 trial of VK0214 in healthy volunteers. VK0214 demonstrated encouraging safety and...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
June 01, 2021
Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA
Via
Benzinga
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
↗
May 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)...
Via
Benzinga
< Previous
1
2
...
23
24
25
26
27
28
29
30
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.